Novartis to Buy Cancer-Drug Maker Endocyte for $2.1 Billion

Novartis said it would buy cancer-drug maker Endocyte for $2.1 billion, the Swiss pharmaceutical giant’s latest move to refocus on higher-value medicines.

Provided by EUPB - Read the full story at the source site.
Read The Full Story

Top News